Stockscreener 앱 받기
168.69
0.14%
0.23
시간 외 거래:
168.69
전일 마감가:
$168.46
열려 있는:
$169.23
하루 거래량:
724.89K
Relative Volume:
0.72
시가총액:
$8.13B
수익:
$4.02B
순이익/손실:
$-142.16M
주가수익비율:
-57.06
EPS:
-2.9563
순현금흐름:
$518.49M
1주 성능:
-9.01%
1개월 성능:
-3.96%
6개월 성능:
-1.64%
1년 성능:
+17.90%
1일 변동 폭
$163.45
$171.02
1주일 범위
$163.45
$194.57
52주 변동 폭
$132.58
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
168.69 | 8.11B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories (CRL) Announces Approval of 2026 Long-Term Incentive Plan - GuruFocus
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock grant - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut - AD HOC NEWS
Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Charles River Laboratories International Inc (CRL) Stock Down 5. - GuruFocus
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - msn.com
Charles River Labs Shareholders Approve New Incentive Plan - TipRanks
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor - Stock Titan
Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant - Stock Titan
Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants - Stock Titan
Director at Charles River (NYSE: CRL) gets 1,438-share equity grant - Stock Titan
Charles River (NYSE: CRL) director receives stock grants instead of fees - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock award - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,973-share equity award - Stock Titan
Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River - Stock Titan
Director James Foster gets 1,860 Charles River (NYSE: CRL) shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Charles River (CRL) Enhances Digital Pathology Platform for Fast - GuruFocus
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow - 01net
Charles River expands AI-enabled digital pathology platform By Investing.com - Investing.com Canada
Charles River Laboratories stock (US1591881009): Core business and market position - AD HOC NEWS
Charles River Laboratories stock: Is CRL underperforming the healthcare sector? - MSN
Is It Time To Rethink Charles River Laboratories (CRL) After Its Recent Price Rebound? - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum - simplywall.st
Charles River Laboratories International Q1 Earnings Call Highlights - Yahoo Finance
MSN Money - MSN
Charles River Laboratories stock (US1591881009): Shares dip after recent run-up as analysts eye upsi - AD HOC NEWS
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Charles River Laboratories Q1 2026 earnings preview - MSN
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results - Benzinga
Charles River Laboratories International, Inc. Seeks M&A Opportunities - marketscreener.com
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2026 Earnings Call Transcript - Insider Monkey
Mizuho raises Charles River Labs stock price target on steady results - Investing.com Canada
Charles River: Q1 Earnings Snapshot - theheraldreview.com
Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance - Moomoo
Johnson Opportunity Fund's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Charles River Laboratories Announces First-Quarter 2026 Results - BioSpace
Charles River Laboratories International, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Charles River Laboratories (CRL) Q1 Loss Of US$14.8m Tests Profitability Recovery Narrative - simplywall.st
Charles River Laboratories International : Quarterly Report for Quarter Ending March 28, 2026 (Form 10-Q) - marketscreener.com
[10-Q] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Quarterly Earnings Report - Stock Titan
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025. - marketscreener.com
Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade) (NYSE:CRL) - Seeking Alpha
Charles River Laboratories International, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:CRL) 2026-05-07 - Seeking Alpha
GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions - PR Newswire
Charles River Laboratories (NYSE:CRL) Beats Q1 Estimates, Reaffirms Guidance - ChartMill
Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Q1 2026 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Labs tops estimates, shares gain on guidance - Investing.com
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
0.56%
자본화:
|
볼륨(24시간):